We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Coming into today, shares of the biopharmaceutical company had gained 6.52% in the past month. In that same time, the Medical sector lost 1.88%, while the S&P 500 lost 7.38%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.55 per share. This would mark year-over-year growth of 135.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.69 billion, down 9.94% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $6.75 per share and a revenue of $45.59 billion, demonstrating changes of +486.96% and -5.6%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.09% higher within the past month. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Bristol Myers Squibb is currently being traded at a Forward P/E ratio of 8.86. This represents a discount compared to its industry's average Forward P/E of 18.77.
Investors should also note that BMY has a PEG ratio of 2.22 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 64, finds itself in the top 26% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
The most recent trading session ended with Bristol Myers Squibb (BMY - Free Report) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Coming into today, shares of the biopharmaceutical company had gained 6.52% in the past month. In that same time, the Medical sector lost 1.88%, while the S&P 500 lost 7.38%.
The upcoming earnings release of Bristol Myers Squibb will be of great interest to investors. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.55 per share. This would mark year-over-year growth of 135.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $10.69 billion, down 9.94% from the year-ago period.
For the full year, the Zacks Consensus Estimates project earnings of $6.75 per share and a revenue of $45.59 billion, demonstrating changes of +486.96% and -5.6%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.09% higher within the past month. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold).
With respect to valuation, Bristol Myers Squibb is currently being traded at a Forward P/E ratio of 8.86. This represents a discount compared to its industry's average Forward P/E of 18.77.
Investors should also note that BMY has a PEG ratio of 2.22 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.51 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 64, finds itself in the top 26% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.